Italia markets closed

Kyowa Kirin Co Ltd (KY4.HA)

Hanover - Hanover Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
20,20+0,30 (+1,51%)
In data: 05:25PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente19,90
Aperto20,20
Denaro20,20 x N/D
Domanda21,00 x N/D
Min-Max giorno20,20 - 20,20
Intervallo di 52 settimane14,00 - 20,20
Volume100
Media Volume0
CapitalizzazioneN/D
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili30 ott 2024 - 04 nov 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Kyowa Kirin to Acquire Orchard Therapeutics

    -Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a t

  • GlobeNewswire

    Tenapanor for Hyperphosphatemia Approved in Japan

    Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced